bluebird bio, Inc. (NASDAQ:BLUE) – Analysts at Oppenheimer issued their Q4 2017 earnings per share (EPS) estimates for bluebird bio in a report released on Wednesday, Zacks Investment Research reports. Oppenheimer analyst M. Breidenbach forecasts that the biotechnology company will earn ($1.79) per share for the quarter. Oppenheimer has a “Hold” rating on the stock. Oppenheimer also issued estimates for bluebird bio’s Q1 2018 earnings at ($1.70) EPS, Q2 2018 earnings at ($1.73) EPS, Q3 2018 earnings at ($1.77) EPS, Q1 2019 earnings at ($1.96) EPS, Q2 2019 earnings at ($2.10) EPS, Q3 2019 earnings at ($1.71) EPS, FY2020 earnings at ($2.06) EPS and FY2021 earnings at $0.64 EPS.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.05). The company had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The company’s quarterly revenue was up 397.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.07) EPS.
Other equities research analysts have also recently issued research reports about the stock. Goldman Sachs Group reiterated a “buy” rating and set a $186.00 price objective on shares of bluebird bio in a research report on Friday, October 6th. Maxim Group reiterated a “buy” rating and set a $170.00 price objective (up previously from $100.00) on shares of bluebird bio in a research report on Monday, October 9th. BMO Capital Markets lifted their price objective on shares of bluebird bio from $134.00 to $162.00 and gave the company a “buy” rating in a research report on Monday, October 30th. BTIG Research upgraded shares of bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 price objective on the stock in a research report on Thursday, November 2nd. Finally, SunTrust Banks lifted their price objective on shares of bluebird bio from $108.00 to $163.00 and gave the company a “buy” rating in a research report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $157.45.
bluebird bio (BLUE) traded down $0.95 during trading on Friday, hitting $170.70. 631,300 shares of the stock traded hands, compared to its average volume of 1,040,000. The company has a market capitalization of $7,820.00, a PE ratio of -24.35 and a beta of 2.08. bluebird bio has a 52-week low of $63.90 and a 52-week high of $222.03.
In other bluebird bio news, insider David Davidson sold 6,000 shares of the business’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $180.30, for a total transaction of $1,081,800.00. Following the transaction, the insider now owns 21,977 shares in the company, valued at $3,962,453.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Nick Leschly sold 10,823 shares of the business’s stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $145.05, for a total transaction of $1,569,876.15. Following the transaction, the chief executive officer now owns 262,409 shares in the company, valued at approximately $38,062,425.45. The disclosure for this sale can be found here. Insiders sold 222,268 shares of company stock worth $38,896,707 in the last 90 days. 3.90% of the stock is currently owned by company insiders.
A number of hedge funds have recently bought and sold shares of the business. Public Employees Retirement System of Ohio bought a new position in bluebird bio during the third quarter valued at $2,725,000. Sterling Capital Management LLC bought a new position in bluebird bio during the third quarter valued at $351,000. California Public Employees Retirement System increased its position in bluebird bio by 1.5% during the third quarter. California Public Employees Retirement System now owns 86,100 shares of the biotechnology company’s stock valued at $11,826,000 after acquiring an additional 1,300 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in bluebird bio by 454.2% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 813 shares during the last quarter. Finally, Crestline Management LP increased its position in bluebird bio by 27.7% during the third quarter. Crestline Management LP now owns 12,594 shares of the biotechnology company’s stock valued at $1,730,000 after acquiring an additional 2,735 shares during the last quarter.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/brokers-issue-forecasts-for-bluebird-bio-inc-s-q4-2017-earnings-blue.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Get a free copy of the Zacks research report on bluebird bio (BLUE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.